How should kidney function be monitored during Sirolimus therapy?

Whole-blood sirolimus trough levels (therapeutic drug monitoring); Urine protein/creatinine ratio at baseline and periodically; Fasting lipid panel (frequent hyperlipidemia); Serum creatinine at baseline and periodically.

How can kidney injury from Sirolimus be prevented?

Therapeutic drug-level monitoring to avoid excessive troughs RAAS blockade (ACE inhibitor or ARB) if proteinuria develops Avoid use in patients with significant pre-existing glomerular injury when alternatives exist

Who is at higher risk of kidney injury from Sirolimus?

Pre-existing chronic kidney disease or reduced GFR; Underlying glomerular disease (e.g., FSGS); Conversion from a calcineurin inhibitor to sirolimus; Higher drug trough levels.

Back to explorer

Printable monograph

mTOR inhibitor

Sirolimus

Rapamune · SIR

mTOR inhibitor · approved 1999 · 13 citations · FAERS AKI reporting ROR 4.60 (95% CI 4.18–5.06, 434 AKI reports)

Dated evidence· through 2019

Deeply sourced8/9 · 7 signals

Met: 13 citations
Met: 12+ references
Met: Accrued over 10+ years (span: 17y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Not met: Current through 2019
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

An mTOR inhibitor long called 'non-nephrotoxic' that can nonetheless unmask podocyte injury, proteinuria, and stall tubular repair.

ModeratemTOR inhibitor

Renal allograft rejection prophylaxis (immunosuppression)Perivascular epithelioid cell tumor (PEComa)LymphangioleiomyomatosisKaposi sarcoma (post-transplant)

§01

Signature kidney injury

Signature lesion

Glomerular Injury / Proteinuria

Representative incidence23.1%

New or worsening proteinuria occurs in a substantial minority of treated patients in transplant cohorts (more pronounced after conversion from a calcineurin inhibitor than with de novo use), but oncology-specific renal incidence is not well quantified and is described largely at the case and small-series level. Acute renal dysfunction (e.g., delayed graft recovery) is recognized but variable. Reported rate: proteinuria in 23.1% — 18 of 78 kidney, pancreas and islet transplant recipients given sirolimus de novo or after conversion, 5 of the 18 (27.8%) reaching nephrotic range; a transplant-immunosuppression figure, not an oncology one (Franco 2007, PMID 17362756).Source: Franco et al., Transplant Proc 2007 (transplant cohort, proteinuria 23.1%); Diekmann, Transplant Rev 2012

Onset & rechallenge

Time to injuryVariable / unpredictable

Weeks to months after initiation or dose escalation; proteinuria often worsens months after calcineurin-inhibitor conversion.

Distilled from: “Variable—weeks to months after initiation or dose escalation; proteinuria characteristically emerges or worsens within months after calcineurin-inhibitor withdrawal/conversion.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Glomerular Injury / Proteinuria#1 · Signature23.1%PMID 17362756 (opens PubMed in a new tab)
proteinuria in ~23% of transplant recipients on sirolimus (de novo or after CNI conversion), occasionally FSGS
Acute Tubular NecrosisSecondaryqualitative — no citable incidence
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

23.1%incidence

SeverityModerate

ReversibilityPartially reversible

Evidence13 citations

Nephron map

GlomerulusFiltration barrier (podocytes + endothelium)

Proximal Tubule

Distal Tubule / Collecting Duct

Glomerular Injury / Proteinuria

Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.

§03

Kidney injury

Mechanism of kidney injury

mTOR inhibition disrupts pathways essential for podocyte integrity: sirolimus lowers podocyte VEGF and interferes with Akt/WT1 signaling, promoting podocyte dedifferentiation and effacement that increases glomerular capillary permeability and causes proteinuria; at high troughs this can manifest as de novo or worsening focal segmental glomerulosclerosis. In parallel, mTORC1 inhibition blunts the compensatory proliferative hypertrophy that surviving podocytes use to cover denuded glomerular basement membrane, accelerating glomerulosclerosis, and suppresses regenerative proliferation of injured proximal tubular epithelium (while favoring apoptosis), impairing recovery from acute tubular injury and contributing to delayed graft function.

Clinical presentation

New or rising proteinuria (subnephrotic to occasionally nephrotic-range with edema and hypoalbuminemia), a creeping serum creatinine, and—when superimposed on existing chronic damage—an acute decline in GFR. Frequently accompanied by the broader sirolimus toxicity profile: hyperlipidemia, cytopenias, mouth ulcers, and impaired wound healing.

Management

Quantify proteinuria and assess GFR; start or optimize ACE inhibitor/ARB therapy and treat dyslipidemia. Reduce dose to lower troughs, and discontinue sirolimus with switch to an alternative agent if proteinuria is progressive (especially nephrotic-range) or renal function declines—proteinuria often improves, though established glomerulosclerosis may persist.Lesion-level management framework

Risk factors

Pre-existing chronic kidney disease or reduced GFR
Underlying glomerular disease (e.g., FSGS)
Conversion from a calcineurin inhibitor to sirolimus
Higher drug trough levels

Prevention

Therapeutic drug-level monitoring to avoid excessive troughs
RAAS blockade (ACE inhibitor or ARB) if proteinuria develops
Avoid use in patients with significant pre-existing glomerular injury when alternatives exist

Anticancer mechanism· how it treats cancer

Binds the immunophilin FKBP12; the sirolimus-FKBP12 complex inhibits mTOR complex 1 (mTORC1), blocking p70S6K/4E-BP1-driven protein synthesis, cell-cycle progression at the G1/S checkpoint, and pro-survival/angiogenic (VEGF) signaling. Used as an antiproliferative immunosuppressant and, within the broader mTOR-inhibitor class (with everolimus and temsirolimus), in oncology settings including renal cell carcinoma, perivascular epithelioid cell tumors, and lymphangioleiomyomatosis.

Note · Historically labeled 'non-nephrotoxic' because it lacks the afferent-arteriolar vasoconstriction of calcineurin inhibitors, but podocyte injury, proteinuria, and impaired tubular repair are well documented in susceptible patients. Renal data derive mainly from transplant and glomerular-disease populations and extend by class reasoning to oncologic mTOR-inhibitor use.

§04

Clinical depth

Renal dose adjustment

No mandatory dose reduction for renal impairment (sirolimus is hepatically metabolized via CYP3A4), but keep troughs toward the lower end and monitor proteinuria when GFR is reduced. Avoid initiating or escalating with significant proteinuria or progressive glomerular disease.

Dialyzability & ESKD dosing

Not meaningfully dialyzable—sirolimus is large, highly lipophilic, extensively (~92%) protein/erythrocyte bound with a very large volume of distribution; hemodialysis does not remove clinically relevant amounts and no supplemental dosing is needed after HD.

Differential diagnosis

Distinguish sirolimus podocytopathy/FSGS from recurrent or primary glomerular disease, transplant-glomerulopathy, and calcineurin-inhibitor arteriolopathy—the temporal link to drug initiation/conversion or high troughs and improvement on dose reduction supports drug attribution; biopsy clarifies FSGS pattern and excludes rejection. Delayed graft function from impaired tubular repair must be separated from acute rejection and ischemic ATN.

Monitoring

Whole-blood sirolimus trough levels (therapeutic drug monitoring)
Urine protein/creatinine ratio at baseline and periodically
Fasting lipid panel (frequent hyperlipidemia)
Serum creatinine at baseline and periodically

Key trials & series

Letavernier CJASN 2007 sirolimus de novo FSGS series
Cho AJKD 2007 sirolimus-in-FSGS trial halted for nephrotoxicity
Diekmann Transplant Rev 2012 mTOR-inhibitor proteinuria analysis

Clinical pearls

Proteinuria classically appears or worsens after switching from a calcineurin inhibitor to sirolimus—check a baseline UPCR before conversion.
Because mTOR inhibition blocks tubular regeneration, avoid starting sirolimus in the early post-transplant or post-ATN window when repair is most needed.
High troughs are the modifiable driver of de novo FSGS—keep levels low and recheck proteinuria after any escalation.

Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the mTOR inhibitor class.

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Non-infectious pneumonitis

Endocrine

Thyroiditis, hypophysitis, diabetes

Hyperglycemia, hyperlipidemia

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Stomatitis

Immune / Infusion

CRS, infusion reactions, irAEs, anaphylaxis

Immunosuppression / infection

§05

References

10 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

10 references · 2002–2019 · 1 since 2017

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedProteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing.Senior PA et al. · Am J Transplant 2005 · PMID 16095517Three islet-transplant recipients developed proteinuria (1-7 g/day) on sirolimus that resolved after sirolimus withdrawal, implicating sirolimus as a direct cause of glomerular proteinuria.CaseC · LimitedThrombotic microangiopathy in marginal kidneys after sirolimus use.Pellé G et al. · Am J Kidney Dis 2005 · PMID 16310579Three recipients of marginal cadaveric kidneys developed de novo thrombotic microangiopathy on sirolimus despite no calcineurin inhibitor exposure, indicating sirolimus-associated renal microvascular injury.CaseC · LimitedSirolimus may promote thrombotic microangiopathy.Saikali JA et al. · Am J Transplant 2003 · PMID 12603218Renal transplant case in which sirolimus appeared to promote thrombotic microangiopathy, a vascular/glomerular form of kidney injury.

FDA label — boxed warning & renal dosing· boxed warning · renal impairment

Quoted verbatim from this agent's current FDA label (Jul 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. O nly physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions ( 5.1 ) ]. The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended [see Warnings and Precautions ( 5.2 , 5.3 ) ]. Liver Transplantation — Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT) The use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss in a study in de novo liver transplant patients. Many of these patients had evidence of infection at or near the time of death. In this and…

Renal impairment — from the label

Dosage adjustment is not required in patients with renal impairment [see Dosage and Administration (2.8), Clinical Pharmacology (12.3) ].

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 13,367 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 7 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Glomerular Injury / Proteinuriacorroborated · ROR 10.33 — on the terms that name the lesion (ROR 10.45)
Acute Tubular Necrosiscorroborated · ROR 9.66

Thrombotic Microangiopathy

ROR 44.3295% CI 40.13–48.95· 413 reports

Glomerular Injury / Proteinuria

ROR 10.3395% CI 8.94–11.93· 188 reports

Acute Tubular Necrosis

ROR 9.6695% CI 7.49–12.46· 60 reports

Acute Interstitial Nephritis

ROR 2.3595% CI 1.62–3.41· 28 reports

Hemorrhagic Cystitis

ROR 2.2195% CI 1.81–2.69· 97 reports

Fanconi Syndrome

ROR 2.1495% CI 1.02–4.50· 7 reports

Electrolyte Disturbance

ROR 1.6595% CI 1.44–1.90· 200 reports

FAERS outcomes & reporting trend· 16.1% of reports w/ death · 34.1% w/ hospitalization

16.1%

Reported with a death outcome

2,150 of 13,367 reports

34.1%

Reported with hospitalization

4,559 of 13,367 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 6 systems · 13,367 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 4.6095% CI 4.18–5.06· 434 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Renal & urinary

Acute Kidney Injury434Renal Impairment270Blood Creatinine Increased242

Immune / infection

Pneumonia487Cytomegalovirus Infection348Infection304Sepsis298Epstein-Barr Virus Infection244

Gastrointestinal

Diarrhoea514Nausea305Vomiting249

General / constitutional

Pyrexia524Fatigue264Multiple Organ Dysfunction Syndrome232

Blood & lymphatic

Thrombotic Microangiopathy376Thrombocytopenia262Neutropenia251

Respiratory

Respiratory Failure233

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Sirolimus sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

mTOR inhibitors (everolimus · temsirolimus)

mTOR inhibitor

Profile

Podocyte injury → proteinuria and FSGS.

GLOMATNTMA

Mild#1 · 79% phenotype match

Datopotamab deruxtecan (Dato-DXd)

Datroway · Antibody-drug conjugate (TROP2/DXd)

Profile

2025 TROP2 ADC; renal signal theoretical, extrapolated from the ADC class.

ATNGLOM

Moderate#2 · 74% phenotype match

Temsirolimus

Torisel · mTOR inhibitor

Profile

Proteinuria and glomerular effects; less firmly quantified than everolimus.

GLOMLYTE

Mild#3 · 61% phenotype match

Erlotinib

Tarceva · EGFR TKI

Profile

Rare minimal-change disease and AKI.

GLOMATNPRE

Mild#4 · 60% phenotype match

Clofarabine

Clolar · Purine analog

Profile

Capillary-leak / SIRS-like AKI and tumor lysis.

PREATNGLOM

Moderate#5 · 57% phenotype match

Ibandronate

Boniva · Bisphosphonate

Profile

Lower renal risk than zoledronate.

ATNLYTEGLOM

Mild#6 · 56% phenotype match

Compare Sirolimus with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across mTOR inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1TemsirolimusGLOM — Glomerular Injury / ProteinuriaMild
2mTOR inhibitors (everolimus · temsirolimus)GLOM — Glomerular Injury / ProteinuriaMild
3Sirolimus· this agentGLOM — Glomerular Injury / ProteinuriaFAERS AKIModerate
4EverolimusGLOM — Glomerular Injury / ProteinuriaFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Sirolimus’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Sirolimus; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 180 clinical records among the 300 most-relevant of 1,071 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.